Central and peripheral effects of prostaglandin E2 and enprostil on exocrine pancreatic secretion in rats.
Prostaglandin E2 (PGE2) has been reported to exert some centrally mediated effects on intestinal motility and secretion and on gastric secretion, but it is not known whether such central effects exist on pancreatic secretion. The central and peripheral effects of PGE2 and enprostil, a long-acting, potent PGE2 analogue, were studied in conscious and anesthetized rats fitted with pancreatic fistulae. In chronically implanted, conscious rats, PGE2 inhibited the secretion of fluid, bicarbonate, and total protein in the pancreatic juice, both after i.v. or intracerebroventricular (icv) injections. The maximal inhibition was similar after both injection procedures (about 45% for fluid and bicarbonate and 60% for protein), but the potency of PGE2 was three to 10 times greater by the icv than the i.v. route. Enprostil also inhibited pancreatic secretion in a dose-related way. The maximal inhibition was larger than after PGE2 injection (about 70% for fluid and bicarbonate and 90% for protein). The potency of enprostil was five to 10 times lower by the icv than by the i.v. route. The diversion of gastric secretion suppressed the effect of icv PGE2 on fluid and bicarbonate output but not on protein and did not change the effect of enprostil on all the variables of pancreatic secretion. Adrenergic antagonists did not suppress the effect of icv PGE2 or enprostil on pancreatic secretion. In anesthetized rats, i.v. PGE2 inhibited hormone-stimulated protein secretion but did not change fluid and bicarbonate output, while i.v. enprostil inhibited cholecystokinin-stimulated fluid, bicarbonate, and protein output in the pancreatic juice.(ABSTRACT TRUNCATED AT 250 WORDS)
Sautereau
D
D
INSERM U 239, Faculté de Médecine Xavier Bichat, Paris, France.
Chovet
M
M
Chariot
J
J
Tsocas
A
A
Rozé
C
C
D000818:Animals; D015232:Dinoprostone / Q000494:pharmacology*; D004146:Dioxanes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D016620:Enprostil; D019329:Idazoxan; D007276:Injections, Intraventricular; D008297:Male; D010179:Pancreas / Q000187:drug effects; D010189:Pancreatic Juice / Q000378:metabolism*; D011224:Prazosin / Q000494:pharmacology; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014630:Vagus Nerve / Q000502:physiology; D015016:Yohimbine / Q000494:pharmacology
D004146:Dioxanes; D011459:Prostaglandins E, Synthetic; D015016:Yohimbine; D016620:Enprostil; D015232:Dinoprostone; D011224:Prazosin; D019329:Idazoxan